Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A game-changer for schizophrenia care just landed. The FDA has approved Weltruza, the first once-monthly subcutaneous injectable form of olanzapine for adults with schizophrenia. Unlike existing options, it requires no loading doses, oral supplementation, or post-injection monitoring — making it a simpler, more adherence-friendly alternative to daily oral medication.
A new monthly shot could help millions stick to schizophrenia treatment
The FDA has approved Weltruza (olanzapine, Teva Pharmaceuticals) — the first once-monthly, subcutaneous, long-acting injectable olanzapine for adults with schizophrenia. The big differentiator? No loading doses, no required oral supplementation, and no post-injection monitoring, addressing major barriers that have long plagued adherence to daily oral treatments.
Of the estimated 1.5 million Americans being treated for schizophrenia, only about 20% currently receive daily oral olanzapine — and adherence remains a persistent challenge. Weltruza aims to close that gap with a simple monthly injection available in three doses (318 mg, 425 mg, and 531 mg), corresponding to existing approved oral doses.
By the Numbers
Why it matters: Medication non-adherence is one of the biggest drivers of relapse in schizophrenia. A once-monthly, easy-to-administer injectable with a clean safety profile could meaningfully reduce hospitalizations and improve long-term outcomes for patients and caregivers alike.
